Bicara Therapeutics (BCAX) Current Assets (2023 - 2026)

Bicara Therapeutics has reported Current Assets for 4 years, with the latest figure at $544.9 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 15.75% year-over-year to $544.9 million; the trailing twelve-month figure through Mar 2026 stood at $544.9 million (up 15.75% YoY), and the FY2025 full-year result was $422.1 million, down 16.01% from the prior year.
• Current Assets for Q1 2026 stood at $544.9 million, up from $422.1 million in the prior quarter.
• The five-year high for Current Assets was $544.9 million in Q1 2026, with the low at $231.1 million in Q4 2023.
• Historically, Current Assets has averaged $429.3 million across 4 years, with a median of $457.6 million in 2025.
• Annual changes were most pronounced in 2024 — Current Assets soared 117.48% — and 2025, when it slumped 42.98%.
• Bicara Therapeutics' Current Assets stood at $231.1 million in 2023, then soared by 117.48% to $502.5 million in 2024, then retreated by 16.01% to $422.1 million in 2025, then advanced by 29.11% to $544.9 million in 2026.
• The last three Current Assets figures came in at $544.9 million (Q1 2026), $422.1 million (Q4 2025), and $297.4 million (Q3 2025), per Business Quant data.